Boston Scientific NIR Primo Monorail Rapid-Exchange Stent Rolls Out In U.S.
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's immediate market release of the NIR Primo Monorail coronary stent system brings to an end U.S. stent market leader Guidant's monopoly of the rapid-exchange niche of the domestic stent market.
You may also be interested in...
Boston Scientific Seeks To Defend Rapid-Exchange Patents In U.S., Abroad
Boston Scientific is seeking to defend the intellectual property gained through its $2.1 bil. Schneider buy in 1998 by filing suit against Medtronic claiming infringement of a rapid-exchange catheter patent.
Boston Scientific Seeks To Defend Rapid-Exchange Patents In U.S., Abroad
Boston Scientific is seeking to defend the intellectual property gained through its $2.1 bil. Schneider buy in 1998 by filing suit against Medtronic claiming infringement of a rapid-exchange catheter patent.
Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.